BUSINESSglobal
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline - Novartis
Single source
Updated 3 hours ago
First seen March 20, 2026 20:38:56Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline Novartis Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion WSJ Novartis to pay $2B upfront for Pikavation and its portfolio targeting PI3Kα FirstWord Pharma Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program Business Wire Novartis makes $3B oncology play Axios